Four monitoring tests:

  • IFX measures serum infliximab (IFX) levels and antibodies to infliximab (ATI)
  • ADA measures serum adalimumab (ADA) levels and antibodies to adalimumab (ATA)
  • VDZ uniquely measures both serum drug concentration and antibodies to vedolizumab levels
  • UST uniquely provides both serum ustekinumab (UST) and antibodies to ustekinumab (ATU) levels any time during treatment

PROMETHEUS® Anser® IFX and PROMETHEUS® Anser® ADA are novel assays that can measure both infliximab or adalimumab and antibody levels from one serum sample and at any time during loss of response. Importantly, they have been verified with more than 4,000 clinical IBD patient samples and, unlike other commercially available monitoring assays, these tests are supported by multiple peer-reviewed publications.

PROMETHEUS® Anser® VDZ is a monitoring test that measures both serum drug concentrations and antibodies to vedolizumab levels even in the presence of vedolizumab from one sample anytime during treatment.

PROMETHEUS® Anser® UST is a new monitoring test that provides valuable information that may help optimize IBD clinical response to ustekinumab


Use PROMETHEUS Anser IFX, PROMETHEUS Anser ADA, PROMETHEUS Anser VDZ and PROMETHEUS Anser UST to help determine personalized solutions for managing loss of response to infliximab, adalimumab, vedolizumab or ustekinumab

Multiple advantages

  • Quantify whether inflammatory bowel disease patients have antibodies and/or sufficient drug concentrations
  • Measure antibodies in the presence of drugs
  • High assay sensitivity, specificity, and accuracy1-3
  • Overcome many of the limitations of solid-phase assays
  • Verified with more than 4,000 clinical IBD patient samples3
 
©2017 Société des Produits Nestlé S.A. Vevey, Switzerland.  All rights reserved.
A Nestlé Health Science Company